Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
// Hio Chung Kang 1, 2, * , Hong Kwan Kim 1, 3, * , Sharon Lee 4 , Pedro Mendez 1 , James Wansoo Kim 4 , Gavitt Woodard 1 , Jun-Hee Yoon 1 , Kuang-Yu Jen 5 , Li Tai Fang 1 , Kirk Jones 5 , David M. Jablons 1, 2 , Il-Jin Kim 1, 2 1 Thoracic Oncology Laboratory, Department of Surgery, University of California San Francisco, San Francisco, CA, USA 2 Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA 3 Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 4 CureSeq Inc, Brisbane, CA, USA 5 Department of Pathology, University of California San Francisco, San Francisco, CA, USA * These authors have contributed equally to this work Correspondence to: Il-Jin Kim, e-mail: Il-Jin.Kim@ucsf.edu David M. Jablons, e-mail: David.Jablons@ucsf.edu Keywords: malignant pleural mesothelioma, multiple primary cancer, genome-wide allelic loss, exome sequencing, SETDB1 Received: October 05, 2015 Accepted: January 15, 2016 Published: January 27, 2016 ABSTRACT Malignant pleural mesothelioma (MPM), a rare malignancy with a poor prognosis, is mainly caused by exposure to asbestos or other organic fibers, but the underlying genetic mechanism is not fully understood. Genetic alterations and causes for multiple primary cancer development including MPM are unknown. We used whole exome sequencing to identify somatic mutations in a patient with MPM and two additional primary cancers who had no evidence of venous, arterial, lymphovascular, or perineural invasion indicating dissemination of a primary lung cancer to the pleura. We found that the MPM had R282W, a key TP53 mutation, and genome-wide allelic loss or loss of heterozygosity, a distinct genomic alteration not previously described in MPM. We identified frequent inactivating SETDB1 mutations in this patient and in 68 additional MPM patients (mutation frequency: 10%, 7/69) by targeted deep sequencing. Our observations suggest the possibility of a new genetic mechanism in the development of either MPM or multiple primary cancers. The frequent SETDB1 inactivating mutations suggest there could be new diagnostic or therapeutic options for MPM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060
Germline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076
Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865
Bott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F., et al. (2011) · Nature · doi:10.1038/nature09806 · Cited by 542 · cited 2×
“SETDB1 is an oncogene frequently amplified in human lung cancers and melanomas [21, 25].”
BackgroundResultMolecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma
Carbone, M., & Yang, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2259 · Cited by 229
Transcriptome sequencing of malignant pleural mesothelioma tumors
Sugarbaker, D. J., Richards, W. G., Gordon, G. J., Dong, L., De Rienzo, A., Maulik, G., Glickman, J. N., Chirieac, L. R., Hartman, M.-L., Taillon, B. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712399105 · Cited by 155
Cited by
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Self-citationSaha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Biological Basis for Novel Mesothelioma Therapies
Obacz, J., Yung, H., Shamseddin, M., Linnane, E., Liu, X., Azad, A. A., Rassl, D. M., Fairen-Jimenez, D., Rintoul, R. C., Nikolić, M. Z., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01462-2 · Cited by 31
Asbestos: Modern Insights for Toxicology in the Era of Engineered Nanomaterials
Felley-Bosco, E., & MacFarlane, M. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00146 · Cited by 23
Napoli, F., Listì, A., Zambelli, V., Witel, G., Bironzo, P., Papotti, M., Volante, M., Scagliotti, G., & Righi, L. (2021) · Cancers · doi:10.3390/cancers13112564 · Cited by 22
Metadata
- Authors
- Kang, H. C., Kim, H. K., Lee, S., Mendez, P., Kim, J. W., Woodard, G., Yoon, J.-H., Jen, K.-Y., Fang, L. T., Jones, K., Jablons, D. M., & Kim, I.-J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-01-27
- Volume
- 7
- Issue
- 7
- Pages
- 8321-8331
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2270944159
- Cited by
- 51
- References
- 7
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.